Stereotaxis (STXS) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
TD Cowen Reiterates Buy Rating on Stereotaxis (STXS)
August 13, 2024 6:08 AM EDTTD Cowen analyst Joshua Jennings reiterated a Buy rating and $5.00 price target on Stereotaxis (NYSE: STXS).
The analyst comments "While hospital construction delays caused 2Q system sale weakness, there are now multiple systems in transit to customers. STXS projects 2H revenue... More
Roth/MKM Reiterates Buy Rating on Stereotaxis (STXS)
August 13, 2024 5:07 AM EDTRoth/MKM analyst Jason Wittes reiterated a Buy rating and $5.00 price target on Stereotaxis (NYSE: STXS).
The analyst comments "STXS reported 2Q24 revenue of $4.5 million vs. consensus/our estimate of $5.6 million. System revenue was $0.2 million vs. consensus of $1.3 million and our estimate of $1.5... More
